Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaozhenfang
- Development stage
- Phase 2
- Lead developer
- Jiangsu Province Hospital on Integration of Chinese and Western Medicine
- Administration
- Oral
01
Overview
Xiaozhenfang is a Traditional Chinese Medicine (TCM) herbal formula developed by the Jiangsu Province Hospital on Integration of Chinese and Western Medicine. It is prepared as a granule for oral administration and is specifically indicated for the prevention and management of dermal toxicity, such as skin rash, in patients receiving epidermal growth factor receptor inhibitors (EGFRIs) for conditions like non-small cell lung cancer (NSCLC). The formula is designed to mitigate the adverse dermatological effects of targeted therapies, thereby enhancing patient adherence and quality of life without interfering with the primary anti-tumor treatment.
- Other names
- Xiaozhenfang granuleXiaozhenfang prescription
Beyond the preview
Go deeper on Xiaozhenfang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiaozhenfang.